Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272141 · ClinicalTrials.gov registry record · Phase 2
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01272141 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 5 participants.
The verdict
NCT01272141, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative breast cancers that are no longer controlled by standard chemotherapy.
Interventions
- DRUG Lapatinib and Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01272141
The ClinicalTrials.gov registry entry for NCT01272141 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lapatinib and Everolimus is the first listed.
NCT01272141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01272141 about?
NCT01272141 is a clinical study titled "A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer". The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalia...
What is the current status of trial NCT01272141?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-12. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01272141?
The interventions under investigation include: Lapatinib and Everolimus (DRUG).
Who is sponsoring clinical trial NCT01272141?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.